Literature DB >> 30023398

The promise and challenges of chimeric antigen receptor T cells in relapsed B-cell acute lymphoblastic leukemia.

Zhi-Chun Ding1.   

Abstract

Entities:  

Year:  2018        PMID： 30023398      PMCID： PMC6035967          DOI： 10.21037/atm.2018.05.35

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

2.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

3.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

Review 4.  CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Authors:  Jae H Park; Mark B Geyer; Renier J Brentjens
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

5.  Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide.

Authors:  Federica Moschella; Mara Valentini; Eleonora Aricò; Iole Macchia; Paola Sestili; Maria Teresa D'Urso; Cristiano Alessandri; Filippo Belardelli; Enrico Proietti
Journal:  Cancer Res       Date:  2011-03-28       Impact factor: 12.701

6.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

Review 7.  Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Authors:  Denis L Jardim; Débora de Melo Gagliato; Francis J Giles; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2017-12-06       Impact factor: 12.531

8.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Authors:  G Gross; T Waks; Z Eshhar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

10.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245
View more
  3 in total

1.  Effects of NRAS Mutations on Leukemogenesis and Targeting of Children With Acute Lymphoblastic Leukemia.

Authors:  Jiabi Qian; Zifeng Li; Kunlin Pei; Ziping Li; Chunjie Li; Muxia Yan; Maoxiang Qian; Yuanbin Song; Hui Zhang; Yingyi He
Journal:  Front Cell Dev Biol       Date:  2022-02-08

2.  Ras pathway mutation feature in the same individuals at diagnosis and relapse of childhood acute lymphoblastic leukemia.

Authors:  Hong-Hong Zhang; Hong-Sheng Wang; Xiao-Wen Qian; Xiao-Hua Zhu; Hui Miao; Yi Yu; Jian-Hua Meng; Jun Le; Jun-Ye Jiang; Ping Cao; Wen-Jing Jiang; Ping Wang; Yang Fu; Jun Li; Mao-Xiang Qian; Xiao-Wen Zhai
Journal:  Transl Pediatr       Date:  2020-02

3.  Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report.

Authors:  Mianzeng Yang; Bingcheng Liu; Ying Wang; Yuntao Liu; Xiaoyuan Gong; Benfa Gong; Yingxi Xu; Yingchang Mi; Min Wang; Jianxiang Wang
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.